These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25254383)

  • 1. Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.
    Singh K; Flores JA; Kirby KA; Neogi U; Sonnerborg A; Hachiya A; Das K; Arnold E; McArthur C; Parniak M; Sarafianos SG
    Viruses; 2014 Sep; 6(9):3535-62. PubMed ID: 25254383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
    Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance in non-subtype B HIV-1.
    Kantor R; Katzenstein D
    J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
    Li S; Ouyang J; Zhao B; An M; Wang L; Ding H; Zhang M; Han X
    BMC Infect Dis; 2020 Feb; 20(1):123. PubMed ID: 32046664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
    Turner D; Shahar E; Katchman E; Kedem E; Matus N; Katzir M; Hassoun G; Pollack S; Kessner R; Wainberg MA; Avidor B
    J Med Virol; 2009 Sep; 81(9):1509-12. PubMed ID: 19626612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
    de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes.
    Giammarino F; de Salazar A; Malet I; Viñuela L; Fuentes A; Saladini F; Bartolini N; Charpentier C; Lambert-Niclot S; Sterrantino G; Colao MG; Micheli V; Bertoli A; Fabeni L; Teyssou E; Delgado R; Falces-Romero I; Aguilera A; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Moreno C; Zazzi M; García F
    J Infect Dis; 2024 Jun; 229(6):1796-1802. PubMed ID: 38206187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
    Santoro MM; Alteri C; Ronga L; Flandre P; Fabeni L; Mercurio F; D'Arrigo R; Gori C; Palamara G; Bertoli A; Forbici F; Salpini R; Boumis E; Tozzi V; Visco-Comandini U; Zaccarelli M; Van Houtte M; Pattery T; Narciso P; Antinori A; Ceccherini-Silberstein F; Perno CF
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1285-93. PubMed ID: 22417570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.
    Theys K; Libin PJK; Van Laethem K; Abecasis AB
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
    Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 17. Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance.
    Muniz CP; Soares MA; Santos AF
    J Antimicrob Chemother; 2014 Oct; 69(10):2741-5. PubMed ID: 24948706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular characterization of complex recombinant HIV-1 CRF06_cpx subtype detected in Turkey].
    Sayan M; Kaptan F; Ormen B; Türker N
    Mikrobiyol Bul; 2014 Jan; 48(1):160-7. PubMed ID: 24506727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.